Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection
Vimalanand S Prabhu, Oliver A Cornely, Yoav Golan, Erik R Dubberke, Sebastian M Heimann, Mary E Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella, Vimalanand S Prabhu, Oliver A Cornely, Yoav Golan, Erik R Dubberke, Sebastian M Heimann, Mary E Hanson, Jane Liao, Alison Pedley, Mary Beth Dorr, Stephen Marcella
Abstract
NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).
Figures
References
- Johnson S, Louie TJ, Gerding DN et al. ; Polymer Alternative for CDI Treatment (PACT) investigators Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345–54.
- Louie TJ, Miller MA, Mullane KM et al. ; OPT-80-003 Clinical Study Group Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422–31.
- Sheitoyan-Pesant C, Abou Chakra CN, Pépin J, Marcil-Héguy A, Nault V, Valiquette L. Clinical and healthcare burden of multiple recurrences of Clostridium difficile infection. Clin Infect Dis 2016; 62:574–80.
- Shivashankar R, Khanna S, Kammer PP et al. . Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther 2014; 40:518–22.
- Bauer MP, Notermans DW, van Benthem BH et al. ; ECDIS Study Group Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63–73.
- Lessa FC, Mu Y, Bamberg WM et al. . Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825–34.
- Morrison RH, Hall NS, Said M et al. . Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis 2011; 53:1173–8.
- See I, Mu Y, Cohen J et al. . NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 2014; 58:1394–400.
- Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012; 18suppl 6:21–7.
- Abou Chakra CN, Pepin J, Sirard S, Valiquette L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014; 9:e98400.
- Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med 2016; 11:56–61.
- Inns T, Gorton R, Berrington A et al. . Effect of ribotype on all-cause mortality following Clostridium difficile infection. J Hosp Infect 2013; 84:235–41.
- Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis 2016; 16:303.
- Asensio A, Di Bella S, Lo Vecchio A et al. . The impact of Clostridium difficile infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. Int J Infect Dis 2015; 36:31–8.
- Le Monnier A, Duburcq A, Zahar JR et al. ; GMC Study Group Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect 2015; 91:117–22.
- Heimann SM, Vehreschild JJ, Cornely OA et al. . Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection 2015; 43:707–14.
- Vincent C, Miller MA, Edens TJ, Mehrotra S, Dewar K, Manges AR. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 2016; 4:12.
- Dubberke ER, Carling P, Carrico R et al. . Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35:628–45.
- Chopra T, Neelakanta A, Dombecki C et al. . Burden of Clostridium difficile infection on hospital readmissions and its potential impact under the Hospital Readmission Reduction Program. Am J Infect Control 2015; 43:314–7.
- Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER. Impact of Clostridium difficile recurrence on hospital readmissions. Am J Infect Control 2015; 43:318–22.
- Wilcox MH, Gerding DN, Poxton IR et al. ; MODIFY I and MODIFY II Investigators Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 2017; 376:305–17.
- Elixhauser A, Steiner C, Gould C. Readmissions following hospitalizations with Clostridium difficile infections, 2009: statistical brief #145 2012. Available at: . Accessed 14 July 2017.
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
- Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302–7.
- Shin JH, Chaves-Olarte E, Warren CA. Clostridium difficile infection. Microbiol Spectr 2016; 4:1–21. doi:10.1128/microbiolspec.EI10-0007-2015.
- Lee CH, Steiner T, Petrof EO et al. . Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 2016; 315:142–9.
- Gerding DN, Meyer T, Lee C et al. . Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 2015; 313:1719–27.
- Carter GP, Chakravorty A, Pham Nguyen TA et al. . Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. MBio 2015; 6:e00551.
- Gupta SB, Mehta V, Dubberke ER et al. . Antibodies to toxin B are protective against Clostridium difficile infection recurrence. Clin Infect Dis 2016; 63:730–4.
- Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012; 55suppl 2:S88–92.
- Shah DN, Aitken SL, Barragan LF et al. . Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect 2016; 93:286–9.
Source: PubMed